Drug-associated cardiovascular risks: a retrospective evaluation of withdrawn drugs

Basit Öğe Kaydı
dc.authoridSemra Şardaş / 0000-0001-5456-8636
dc.authorscopusidSemra Şardaş / 7003286974
dc.authorwosidSemra Şardaş / J-2175-2018
dc.contributor.authorKocadal, Kumsal
dc.contributor.authorSaygı, Sahan
dc.contributor.authorAlkaş, Fehmi Burak
dc.contributor.authorŞardaş, Semra
dc.date.accessioned2020-08-30T20:07:06Z
dc.date.available2020-08-30T20:07:06Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümüen_US
dc.description.abstractA considerable number of drugs were withdrawn from the world market in the last decades due to safety reasons. A retrospective review of withdrawals is important in determining the adequacy of regulations regarding the safety and efficacy of drugs. The scope of the present study was to focus on cardiovascular adverse reactions of 61 withdrawn medicinal products, as well as 40 additional drugs withdrawn due to non-cardiovascular toxicity, while being cardiovascular agents themselves. A detailed web-based data search was held to draw a list of withdrawn pharmaceutical products from the pharmaceutical market by regulatory authorities between 1950 and 2017 due to safety reasons. A total of 464 medicinal products were withdrawn from the pharmaceutical markets between 1950 and 2017 due to safety reasons. Hepatotoxicity was the most commonly reported adverse drug reaction (ADR) that led to withdrawal, followed by immune-related reactions, neurotoxicity, and cardiovascular toxicity. The underlying mechanisms leading to cardiovascular toxicity should be investigated in depth to avoid the use of risky drugs for long periods, especially in consideration of the fact that some cardiovascular drugs persisted in the market for many decades. Furthermore, improved reporting of suspected adverse reactions and stricter regulations will lead to quicker detection of ADRs, thus emphasizing the importance of this public health problem and highlighting the need for improved "early warning systems" to manage the risks of high-risk drugs.en_US
dc.identifier.citationKocadal, K., Saygi, S., Alkas, F. B., & Sardas, S. (2019). Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs. Northern clinics of Istanbul, 6(2), 196.en_US
dc.identifier.doi10.14744/nci.2018.44977en_US
dc.identifier.endpage202en_US
dc.identifier.issn2148-4902en_US
dc.identifier.issue2en_US
dc.identifier.pmid31297490en_US
dc.identifier.startpage196en_US
dc.identifier.trdizinid337879en_US
dc.identifier.urihttps://doi.org/10.14744/nci.2018.44977
dc.identifier.urihttps://hdl.handle.net/20.500.12713/695
dc.identifier.volume6en_US
dc.identifier.wosWOS:000472063600017en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorŞardaş, Semraen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofNorthern Clinics of Istanbulen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCardiovascular Toxicityen_US
dc.subjectDrug Safetyen_US
dc.subjectDrug Withdrawalen_US
dc.titleDrug-associated cardiovascular risks: a retrospective evaluation of withdrawn drugsen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4a.pdf
Boyut:
233.67 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Meslek Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu